Allurion Technologies, Inc. (ALUR) Announces Q2 Loss and Falls Short of Revenue Projections
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2025
0mins
Should l Buy A?
Source: NASDAQ.COM
Quarterly Performance: Allurion Technologies, Inc. reported a quarterly loss of $0.57 per share, better than the expected loss of $0.65, but down from earnings of $0.25 per share a year ago.
Revenue Miss: The company generated revenues of $3.38 million for the quarter, missing estimates by 43.21% and significantly lower than $11.77 million from the previous year.
Stock Outlook: Allurion's shares have dropped about 78% this year, with current consensus EPS estimates indicating continued losses; the stock holds a Zacks Rank #4 (Sell), suggesting it may underperform in the near future.
Industry Context: The Medical - Products industry ranks in the top 39% of Zacks industries, which could influence Allurion's performance, while Agilent Technologies is set to report its results soon, with expectations of modest growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy A?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on A
Wall Street analysts forecast A stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 110.240
Low
160.00
Averages
171.67
High
180.00
Current: 110.240
Low
160.00
Averages
171.67
High
180.00
About A
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
The Overlooked Sector of Healthcare That Has Captivated Wall Street
Health Care Industry Volatility: The health care sector is characterized by significant volatility, with companies experiencing drastic changes in stock prices based on the success of individual products or clinical trials.
Investment Trends: Investors are increasingly focusing on companies that provide essential equipment and services rather than high-risk pharmaceutical names, despite some major players in the lab equipment sector being overlooked.
Thermo Fisher's Performance: Thermo Fisher Scientific has faced challenges in 2026, with shares dropping over 15% year-to-date, but recent revenue growth and strong earnings suggest potential for recovery.
Agilent's Growth Potential: Agilent Technologies is expected to see significant growth in earnings and share price, driven by its recent acquisition of BioCare Medical, which enhances its capabilities in cancer diagnostics.
See More
Agilent Receives FDA Approval for New Diagnostic Tool
- FDA Approval for New Indication: Agilent Technologies announced that its PD-L1 IHC 22C3 pharmDx (Code SK006) has received FDA approval as a companion diagnostic to help identify patients with esophageal or gastroesophageal junction carcinoma eligible for Merck's KEYTRUDA treatment, further solidifying its position in precision medicine.
- Eighth Indication: This approval marks the eighth FDA-approved indication for PD-L1 IHC 22C3 pharmDx, showcasing the product's broad application potential in cancer treatment, which may drive Agilent's growth in the clinical diagnostics market.
- Positive Market Reaction: In pre-market trading on the NYSE, Agilent shares rose by 0.46% to $113.48, reflecting investor confidence in the company's newly approved product and optimistic expectations for its future market performance.
- Supporting Clinical Decisions: Nina Green, Vice President and General Manager of Agilent's Clinical Diagnostics Division, stated that the expanded FDA approval of PD-L1 IHC 22C3 pharmDx will assist clinicians in better identifying patients suitable for KEYTRUDA treatment, thereby enhancing treatment efficacy and patient survival rates.
See More
Agilent Receives FDA Approval for New Diagnostic Tool
- FDA Approval: Agilent Technologies has received FDA approval for PD-L1 IHC 22C3 pharmDx as a companion diagnostic tool aimed at identifying patients with esophageal or gastroesophageal junction carcinoma eligible for KEYTRUDA treatment, marking a significant advancement in the field of precision medicine.
- Market Demand Response: This diagnostic tool is specifically designed to identify patients with PD-L1 expression ≥ 1, which is expected to significantly enhance treatment options for esophageal cancer patients, addressing the urgent market demand for precision therapies and reinforcing Agilent's leadership in the cancer diagnostics market.
- Multiple Indications: In addition to esophageal cancer, PD-L1 IHC 22C3 pharmDx is also indicated for identifying patients with non-small cell lung cancer, cervical cancer, and other cancers, thereby broadening its market application and enhancing Agilent's product competitiveness.
- Strong Financial Performance: Agilent reported revenues of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people; with the launch of this new diagnostic tool, future revenue growth is anticipated, solidifying its position in the global clinical diagnostics market.
See More
Crawford & Company Appoints New CEO
- New CEO Appointment: Crawford & Company has appointed W. Bruce Swain Jr. as President and CEO effective immediately, having served in an interim capacity since January 1, which reflects the company's confidence in his leadership capabilities.
- Board Changes: Board member Jesse C. Crawford Sr. announced he will not seek re-election at the 2026 annual shareholder meeting, marking the end of over four decades with the firm, indicating a significant shift in the company's governance structure.
- Honorary Title Bestowal: Following the shareholder meeting, Crawford Sr. will be named an honorary board member and emeritus officer, recognizing his long-term contributions while facilitating a smooth transition to the new board.
- Future Outlook: The company anticipates a subdued claims environment in Q1 2026, reflecting current market challenges and uncertainties that may impact overall performance, highlighting the need for strategic adjustments moving forward.
See More
Agilent Launches Advanced Therapeutics CDMO Solution
- Integrated Manufacturing Capabilities: Agilent's launch of the Advanced Therapeutics solution combines the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado, offering a comprehensive suite of customizable manufacturing services that enhance the company's competitiveness in the biopharmaceutical sector.
- Diverse Product Portfolio: The CDMO portfolio includes oligonucleotides, microbial fermentation, complex synthetic chemistry, highly potent APIs, and cell line development, catering to diverse client needs in clinical and commercial-scale production, thereby driving business growth.
- Enhanced Customer Experience: By providing a streamlined, end-to-end service from discovery to clinical and commercial-scale manufacturing, Agilent creates a more integrated experience for clients, deepening technical partnerships and building customer trust.
- Long-Term Commitment: Agilent's CEO Padraig McDonnell emphasizes that this launch reflects the company's long-term commitment to growth, investment, and leadership in the industry, aimed at supporting clients in developing life-changing therapies.
See More
Agilent Acquires Biocare Medical for $950 Million
- Acquisition Overview: Agilent Technologies announced the acquisition of Biocare Medical for approximately $950 million, with the deal expected to close in the fourth fiscal quarter of 2026, enhancing its market position in pathology.
- Growth Potential: Biocare Medical boasts over 300 specialized antibodies and strong R&D capabilities, achieving double-digit revenue and profit growth since 2021, which is anticipated to significantly boost Agilent's revenue growth and margins.
- Market Integration Impact: The acquisition will integrate Biocare's product portfolio into Agilent's Life Sciences and Diagnostics Markets Group, expected to enhance its ability to develop and commercialize new IVD antibodies, thereby expanding its reach across clinical and research pathology labs.
- Stock Performance Analysis: Despite a 5.60% decline in Agilent's stock over the past 12 months, currently trading at $116.41, below its 20-day and 50-day SMAs, the strategic acquisition of Biocare may improve its market performance in the future.
See More
The Overlooked Sector of Healthcare That Has Captivated Wall Street
Health Care Industry Volatility: The health care sector is characterized by significant volatility, with companies experiencing drastic changes in stock prices based on the success of individual products or clinical trials.
Investment Trends: Investors are increasingly focusing on companies that provide essential equipment and services rather than high-risk pharmaceutical names, despite some major players in the lab equipment sector being overlooked.
Thermo Fisher's Performance: Thermo Fisher Scientific has faced challenges in 2026, with shares dropping over 15% year-to-date, but recent revenue growth and strong earnings suggest potential for recovery.
Agilent's Growth Potential: Agilent Technologies is expected to see significant growth in earnings and share price, driven by its recent acquisition of BioCare Medical, which enhances its capabilities in cancer diagnostics.
See More
Agilent Receives FDA Approval for New Diagnostic Tool
- FDA Approval for New Indication: Agilent Technologies announced that its PD-L1 IHC 22C3 pharmDx (Code SK006) has received FDA approval as a companion diagnostic to help identify patients with esophageal or gastroesophageal junction carcinoma eligible for Merck's KEYTRUDA treatment, further solidifying its position in precision medicine.
- Eighth Indication: This approval marks the eighth FDA-approved indication for PD-L1 IHC 22C3 pharmDx, showcasing the product's broad application potential in cancer treatment, which may drive Agilent's growth in the clinical diagnostics market.
- Positive Market Reaction: In pre-market trading on the NYSE, Agilent shares rose by 0.46% to $113.48, reflecting investor confidence in the company's newly approved product and optimistic expectations for its future market performance.
- Supporting Clinical Decisions: Nina Green, Vice President and General Manager of Agilent's Clinical Diagnostics Division, stated that the expanded FDA approval of PD-L1 IHC 22C3 pharmDx will assist clinicians in better identifying patients suitable for KEYTRUDA treatment, thereby enhancing treatment efficacy and patient survival rates.
See More
Agilent Receives FDA Approval for New Diagnostic Tool
- FDA Approval: Agilent Technologies has received FDA approval for PD-L1 IHC 22C3 pharmDx as a companion diagnostic tool aimed at identifying patients with esophageal or gastroesophageal junction carcinoma eligible for KEYTRUDA treatment, marking a significant advancement in the field of precision medicine.
- Market Demand Response: This diagnostic tool is specifically designed to identify patients with PD-L1 expression ≥ 1, which is expected to significantly enhance treatment options for esophageal cancer patients, addressing the urgent market demand for precision therapies and reinforcing Agilent's leadership in the cancer diagnostics market.
- Multiple Indications: In addition to esophageal cancer, PD-L1 IHC 22C3 pharmDx is also indicated for identifying patients with non-small cell lung cancer, cervical cancer, and other cancers, thereby broadening its market application and enhancing Agilent's product competitiveness.
- Strong Financial Performance: Agilent reported revenues of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people; with the launch of this new diagnostic tool, future revenue growth is anticipated, solidifying its position in the global clinical diagnostics market.
See More
Crawford & Company Appoints New CEO
- New CEO Appointment: Crawford & Company has appointed W. Bruce Swain Jr. as President and CEO effective immediately, having served in an interim capacity since January 1, which reflects the company's confidence in his leadership capabilities.
- Board Changes: Board member Jesse C. Crawford Sr. announced he will not seek re-election at the 2026 annual shareholder meeting, marking the end of over four decades with the firm, indicating a significant shift in the company's governance structure.
- Honorary Title Bestowal: Following the shareholder meeting, Crawford Sr. will be named an honorary board member and emeritus officer, recognizing his long-term contributions while facilitating a smooth transition to the new board.
- Future Outlook: The company anticipates a subdued claims environment in Q1 2026, reflecting current market challenges and uncertainties that may impact overall performance, highlighting the need for strategic adjustments moving forward.
See More
Agilent Launches Advanced Therapeutics CDMO Solution
- Integrated Manufacturing Capabilities: Agilent's launch of the Advanced Therapeutics solution combines the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado, offering a comprehensive suite of customizable manufacturing services that enhance the company's competitiveness in the biopharmaceutical sector.
- Diverse Product Portfolio: The CDMO portfolio includes oligonucleotides, microbial fermentation, complex synthetic chemistry, highly potent APIs, and cell line development, catering to diverse client needs in clinical and commercial-scale production, thereby driving business growth.
- Enhanced Customer Experience: By providing a streamlined, end-to-end service from discovery to clinical and commercial-scale manufacturing, Agilent creates a more integrated experience for clients, deepening technical partnerships and building customer trust.
- Long-Term Commitment: Agilent's CEO Padraig McDonnell emphasizes that this launch reflects the company's long-term commitment to growth, investment, and leadership in the industry, aimed at supporting clients in developing life-changing therapies.
See More
Agilent Acquires Biocare Medical for $950 Million
- Acquisition Overview: Agilent Technologies announced the acquisition of Biocare Medical for approximately $950 million, with the deal expected to close in the fourth fiscal quarter of 2026, enhancing its market position in pathology.
- Growth Potential: Biocare Medical boasts over 300 specialized antibodies and strong R&D capabilities, achieving double-digit revenue and profit growth since 2021, which is anticipated to significantly boost Agilent's revenue growth and margins.
- Market Integration Impact: The acquisition will integrate Biocare's product portfolio into Agilent's Life Sciences and Diagnostics Markets Group, expected to enhance its ability to develop and commercialize new IVD antibodies, thereby expanding its reach across clinical and research pathology labs.
- Stock Performance Analysis: Despite a 5.60% decline in Agilent's stock over the past 12 months, currently trading at $116.41, below its 20-day and 50-day SMAs, the strategic acquisition of Biocare may improve its market performance in the future.
See More
